Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Hemorrhagic Fever, Ebola
Interventions
BIOLOGICAL

rVSVΔ-ZEBOV-GP

single dose of rVSVΔ-ZEBOV-GP (3x10\^6 pfu, 2x10\^7 pfu or 3x10\^5)

Trial Locations (1)

20246

CTC North GmbH & Co. KG, Hamburg

All Listed Sponsors
collaborator

German Center for Infection Research

OTHER

collaborator

Philipps University Marburg

OTHER

collaborator

World Health Organization

OTHER

collaborator

Clinical Trial Center North

UNKNOWN

collaborator

University Hospital, Geneva

OTHER

collaborator

Albert Schweitzer Hospital

OTHER

collaborator

Institute of Tropical Medicine, University of Tuebingen

OTHER

collaborator

Wellcome Trust

OTHER

collaborator

KEMRI-Wellcome Trust Collaborative Research Program

OTHER

lead

Universitätsklinikum Hamburg-Eppendorf

OTHER